Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial

Autor: Kobbernagel, Helene E, Buchvald, Frederik F, Haarman, Eric G, Casaulta, Carmen, Collins, Samuel A, Hogg, Claire, Kuehni, Claudia E, Lucas, Jane S, Moser, Claus E, Quittner, Alexandra L, Raidt, Johanna, Rosthøj, Susanne, Sørensen, Anne L, Thomsen, Kim, Werner, Claudius, Omran, Heymut, Nielsen, Kim G ^*

Publikováno v: In The Lancet Respiratory Medicine May 2020 8(5):493-505

Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52‐week randomized controlled clinical trial.

Autor: Foghsgaard, Signe, Vedtofte, Louise, Andersen, Emilie S., Bahne, Emilie, Andreasen, Camilla, Sørensen, Anne L., Forman, Julie L., Mathiesen, Elisabeth R., Svare, Jens A., Clausen, Tine D., Damm, Peter, Holst, Jens J., Knop, Filip K., Vilsbøll, Tina

Publikováno v: Diabetes, Obesity & Metabolism; Jan2024, Vol. 26 Issue 1, p201-214, 14p

Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia:The HypoDeg randomized, controlled, open-label, crossover trial

Autor: Pedersen-Bjergaard, Ulrik, Agesen, Rikke M., Brøsen, Julie M. B., Alibegovic, Amra C., Andersen, Henrik U., Beck-Nielsen, Henning, Gustenhoff, Peter, Hansen, Troels K., Hedetoft, Christoffer, Jensen, Tonny J., Juhl, Claus B., Jensen, Andreas K., Lerche, Susanne S., Nørgaard, Kirsten, Parving, Hans-Henrik, Sørensen, Anne L., Tarnow, Lise, Thorsteinsson, Birger

Publikováno v: Pedersen-Bjergaard, U, Agesen, R M, Brøsen, J M B, Alibegovic, A C, Andersen, H U, Beck-Nielsen, H, Gustenhoff, P, Hansen, T K, Hedetoft, C, Jensen, T J, Juhl, C B, Jensen, A K, Lerche, S S, Nørgaard, K, Parving, H-H, Sørensen, A L, Tarnow, L & Thorsteinsson, B 2022, ' Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia : The HypoDeg randomized, controlled, open-label, crossover trial ', Diabetes, Obesity and Metabolism, vol. 24, no. 2, pp. 257-267 . https://doi.org/10.1111/dom.14574
Pedersen-Bjergaard, U, Agesen, R M, Brøsen, J M B, Alibegovic, A C, Andersen, H U, Beck-Nielsen, H, Gustenhoff, P, Hansen, T K, Hedetoft, C, Jensen, T J, Juhl, C B, Jensen, A K, Lerche, S S, Nørgaard, K, Parving, H H, Sørensen, A L, Tarnow, L & Thorsteinsson, B 2022, ' Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia : The HypoDeg randomized, controlled, open-label, crossover trial ', Diabetes, Obesity and Metabolism, vol. 24, no. 2, pp. 257-267 . https://doi.org/10.1111/dom.14574
Pedersen-Bjergaard, U, Agesen, R M, Brosen, J M B, Alibegovic, A C, Andersen, H U, Beck-Nielsen, H, Gustenhoff, P, Hansen, T K, Hedetoft, C, Jensen, T J, Juhl, C B, Jensen, A K, Lerche, S S, Norgaard, K, Parving, H-H, Sørensen, A L, Tarnow, L & Thorsteinsson, B 2022, ' Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia : The HypoDeg randomized, controlled, open-label, crossover trial ', Diabetes, Obesity and Metabolism, vol. 24, no. 2, pp. 257-267 . https://doi.org/10.1111/dom.14574

AIMS/HYPOTHESIS: Nocturnal hypoglycaemia remains a main limiting factor for achieving the recommended glycaemic target in type 1 diabetes (T1D). The long-acting insulin analogue degludec reduces the risk of nocturnal hypoglycaemia in patients with T1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ea20a7929bda2805a25ff56acc204d8d
https://vbn.aau.dk/da/publications/abad2c29-53c3-427f-9fea-bc6c4317390e

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.